Please login to the form below

lenalidomide

This page shows the latest lenalidomide news and features for those working in and with pharma, biotech and healthcare.

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa

The anti-CD38 antibody is an option for patients who have been treated with at least two prior therapies, including BMS’ Revlimid (lenalidomide) and a proteasome inhibitor such as Takeda’s

Latest news

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

The 750-patrient ELOQUENT-1 trial showed that adding Empliciti (elotuzumab) to background treatment with BMS/Celgene’s Revlimid (lenalidomide) and dexamethasone didn’t extend the time patients with newly-diagnosed
FDA approves Sanofi’s key cancer drug Sarclisa for myeloma

Sarclisa will now be available for patients with relapsed or refractor multiple myeloma who have received at least two prior therapies, including Celgene’s Revlimid (lenalidomide) and a proteasome inhibitor.
Celgene’s Revlimid scores NICE approval in follicular lymphoma

Lenalidomide is a new type of targeted cancer therapy for people with previously treated follicular lymphoma. ... Lenalidomide fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease
Janssen files new Darzalex combination for multiple myeloma

It also has an approval for another combination regimen made up of Darzalex, Celgene’s Revlimid (lenalidomide) and dexamethasone, for the treatment of newly diagnosed multiple myeloma patients who are ineligible
Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls

to the contribution of drugs like blockbuster blood cancer drug Revlimid (lenalidomide).

More from news
Approximately 14 fully matching, plus 102 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma companies to watch

BMS will become the fourth largest pharma firm by sales – behind Pfizer, Novartis and Roche – and the addition of new Celgene brands like blood cancer therapies Revlimid (lenalidomide) and Pomalyst (pomalidomide)
European biotech: a new generation of leaders emerges

The phase 2 L-MIND study in diffuse large B-cell lymphoma (DLBCL) showed the combination of tafasitamab with Celgene’s Revlimid (lenalidomide) had an overall response rate of 60%, with
Building a business that is lean and specialised

drug Revlimid (lenalidomide).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments

Lenalidomide. Revlimid. Celgene. Thalidomide. Thalomid. Celgene. Melphalan. Multiple brands. -. Erlotinib. Tarceva. Genentech. Front-line treatment of EGFR mutation positive advanced non-small cell lung cancer.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months: A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up: COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020: In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...